-
公开(公告)号：US11471482B2
公开(公告)日：2022-10-18
申请号：US16955096
申请日：2018-12-18
Applicant: NANOBIOTIX S.A.
Inventor： Agnès Pottier , Laurent Levy , Marie-Edith Meyre
IPC: A61K9/51 , A61K33/242 , A61K9/00 , A61K33/243 , B82Y5/00
Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above (200), and an insulator material with a dielectric constant εijk equal to or below (100). It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source such as a light source, a magnetic field, or an ultrasound source.
-
公开(公告)号：US10391058B2
公开(公告)日：2019-08-27
申请号：US15529101
申请日：2015-11-24
Applicant: NANOBIOTIX
Inventor： Matthieu Germain , Marie-Edith Meyre , Agnes Pottier , Laurent Levy
IPC: A61K9/127 , A61K9/51 , A61K9/00 , A61K31/704
Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a first biocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle.
-
公开(公告)号：US10413509B2
公开(公告)日：2019-09-17
申请号：US14892271
申请日：2014-05-30
Applicant: NANOBIOTIX
Inventor： Agnés Pottier , Laurent Levy , Marie-Edith Meyre , Audrey Darmon , Matthieu Germain
IPC: A61K9/127 , A61K9/51 , A61K31/704 , A61K9/00 , A61K9/14
Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.
-
4.发明申请NANOPARTICLES COMPRISING METALLIC AND HAFNIUM OXIDE MATERIALS, PREPARATION AND USES THEREOF 审中-公开包含金属和氧化铌材料的纳米颗粒，其制备及其用途公开(公告)号：US20140335015A1
公开(公告)日：2014-11-13
申请号：US14364859
申请日：2012-12-17
Applicant: NANOBIOTIX
Inventor： Agnes Pottier , Laurent Levy , Marie-Edith Meyre
CPC classification number: A61K9/5115 , A61K9/0009 , A61K9/51 , A61K33/24 , A61K41/0038 , A61K41/0052 , A61K49/00 , A61K49/04 , A61K51/1244 , A61K2123/00 , A61N5/10
Abstract: The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.
Abstract translation: 本发明涉及可有益地用于卫生部门作为诊断和/或治疗剂的新型纳米颗粒。 本发明的纳米颗粒包括至少部分地被氧化铪材料覆盖或嵌入其中的金属材料。 与现有产品相比，这些纳米颗粒比风险比提供了显着的优势。 具体地说，这些纳米粒子增强已知金属纳米粒子的效率。 实际上，它们保留金属固有性质，现在另外可安全地用于哺乳动物，特别是人类。 本发明还涉及制备所述纳米颗粒的方法，含有该纳米颗粒的组合物及其用途。
-
公开(公告)号：US11497717B2
公开(公告)日：2022-11-15
申请号：US16955092
申请日：2018-12-18
Applicant: NANOBIOTIX S.A.
Inventor： Marie-Edith Meyre , Laurent Levy , Agnès Pottier
Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.
-
Patent Agency Ranking
公开(公告)号：US11229705B2
公开(公告)日：2022-01-25
申请号：US16472216
申请日：2017-12-19
Applicant: NANOBIOTIX
Inventor： Agnès Pottier , Laurent Levy , Marie-Edith Meyre
Abstract: The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use for modulating electrical polarization of neurons in a subject, for example for use in prevention or treatment of a neuronal disease in a subject, typically by modulating electrical polarization of neurons in the subject, wherein i) when the nanoparticle or nanoparticles' aggregate is exposed to a light source, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, ii) when the nanoparticle or nanoparticles' aggregate is exposed to a magnetic field, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling magneto-electric transduction or magneto-thermal transduction, iii) when the nanoparticle or nanoparticles' aggregate's surface is exposed to an ultrasound source, the nanoparticle's or nanoparticles' aggregate's material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticles' aggregate is either neutrally charged in the absence of any coating or is coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticles' aggregate. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
公开(公告)号：US10064962B2
公开(公告)日：2018-09-04
申请号：US14886326
申请日：2015-10-19
Inventor： Agnés Pottier , Laurent Levy , Marie-Edith Meyre , Matthieu Germain , Cyril Lorenzato , Chrit Moonen , Pierre Smirnov
IPC: A61K9/127 , A61K49/18 , A61K9/00 , A61K9/50 , A61K9/51 , A61K41/00 , A61K31/704 , G01N24/08 , G01R33/56
Abstract: The invention pertains to a method of monitoring the membrane permeabilization of a liposome and the incidental release of a compound of interest. The method utilizes liposomes comprising a thermosensitive lipidic membrane encapsulating the product of interest and superparamagnetic nanoparticles having the electrostatic surface charge below −20 mV or above +20 mV when measured in an aqueous medium at physiological pH. In one embodiment, the method comprises the steps of: a) measuring relaxation time (T2*); b) heating the liposome at Tm or above Tm; c) measuring T2* after step b); d) obtaining the transverse relaxivity (r2*) values from the T2* values obtained from step a) and step c); and e) determining the ratio of r2* before and after the heating step b). A ratio above 1.5 indicates the liposome membrane permeabilization and the incidental release of the product of interest.
-
公开(公告)号：US11717684B2
公开(公告)日：2023-08-08
申请号：US17697976
申请日：2022-03-18
Applicant: NANOBIOTIX S.A.
Inventor： Marie-Edith Meyre , Agnès Pottier , Laurent Levy
CPC classification number: A61N1/36025 , A61K41/0052 , A61N2/006 , A61P25/00 , B82Y40/00
Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
公开(公告)号：US11278723B2
公开(公告)日：2022-03-22
申请号：US16472214
申请日：2017-12-19
Applicant: NANOBIOTIX S.A.
Inventor： Marie-Edith Meyre , Agnès Pottier , Laurent Levy
Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
公开(公告)号：US11247054B2
公开(公告)日：2022-02-15
申请号：US16472215
申请日：2017-12-19
Applicant: NANOBIOTIX S.A.
Inventor： Laurent Levy , Marie-Edith Meyre , Agnès Pottier
Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and to the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject when the nanoparticle and/or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.018 seconds)
